NexPoint Funds I NexPoint Merger Arbitrage Fund Class Z Shares - HMEZX Annual Shareholder Report - June 30, 2024

NEXPOINT

This annual shareholder report contains important information about Class Z Shares of the NexPoint Merger Arbitrage Fund (the "Fund") for the period from July 1, 2023 to June 30, 2024. You can find additional information about the Fund at https://www.nexpoint.com/nexpoint/funds/nexpoint-merger-arbitrage-fund/. You can also request this information by contacting us at 1-877-655-1287.

What were the Fund costs for the last year?


(based on a hypothetical \$10,000 investment)

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
NexPoint Merger Arbitrage Fund, Class Z Shares	\$217	2.09%

How did the Fund perform in the last year?

For the twelve-month period ended June 30, 2024, the NexPoint Merger Arbitrage Fund (the "Fund") Class Z returned 8.01% compared to the Bloomberg U.S. Aggregate Bond Index return of 2.63%. During this period, the use of securities sold short offset the Fund's return (0.39%) and the use of derivatives gained 0.31% to the Fund's return. This outperformance of the Bloomberg U.S. Aggregate Bond Index is largely attributable to the idiosyncratic nature of the merger arbitrage strategy and deal spreads pricing at a premium to the front end of the yield curve. The front end of the yield curve are the yields on U.S. Treasuries with maturities less than 2 years. These Treasury yields effectively set a floor for the yields in merger arbitrage investments, and yields in merger arbitrage investments are at a premium/spread above such U.S. Treasuries. Our correlation to the Bloomberg U.S. Aggregate Bond Index remained low at 0.058. Furthermore, the Fund's outperformance is attributable to our active management of the Fund.

- Top Contributor: HZNP / AMGEN Deal: Horizon Therapeutics a biotechnology company focused on rare, autoimmune, and severe inflammatory diseases agreed to be acquired by Amgen for \$27.0 billion.
- Top Detractor: OLK / TMO Deal: Olink a proteomics technology platform company that enables protein analysis capabilities for the biopharmaceutical industry agreed to be acquired by Thermo for \$3.2 billion.



Total Return Based on \$10,000 Investment

Average Annual Total Returns as of June 30, 2024

			Annualized
			Since
Fund/Index Name	<u>1 Year</u>	<u>5 Years</u>	Inception
NexPoint Merger Arbitrage Fund, Class Z Shares	7.95%	5.72%	5.80%
Bloomberg U.S. Aggregate Bond Index (USD)	2.63%	-0.23%	1.07%

The line graph represents historical performance of a hypothetical investment of \$10,000 in the Fund during the last 10 years. Returns shown are total returns, which assume the reinvestment of dividends and capital gains. The table and graph presented above do not reflect the deduction of taxes a shareholder would pay on Fund distributions or the redemption of Fund Shares. **Past performance is not indicative of future performance.** Call 1-877-655-1287 or

visit https://www.nexpoint.com/nexpoint/funds/nexpoint-merger-arbitrage-fund/ for current monthend performance.

Key Fund Statistics as of June 30, 2024							
Total Net Assets	Number of Holdings	Total Advisory Fees Paid	Portfolio Turnover Rate				
\$790,876,327	83	\$6,013,862	556%				

What did the Fund invest in?

Asset Weightings*		Top Positions	
		Holding Name Long Securities	<u>Percentage of Total Net Assets^(A)</u>
Common Stocks	56.9%	Encore Wire	7.8%
Asset-Backed Securities	11.9%	Everbridge	6.3%
Corporate Obligations	11.9%	US Silica Holdings	4.2%
Cash Equivalent	5.8%	Endeavor Group Holdings	4.0%
Convertible Bonds	1.5%	National Western Life Group	4.0%
Repurchase Agreements	0.5%	Short Securities	
Special Purchase Acquisition Companies	0.5%	Chevron	-3.3%
Purchased Put Option	0.2%	International Paper	-1.2%
Rights	0.0%	ConocoPhillips	-1.0%
Preferred Stocks	0.0%	McGrath RentCorp	-0.4%
Warrants	0.0%	United States Steel Corporation	-0.4%
Derivative Contracts (Net)	-0.5%		
Common Stocks Sold Short	-5.8%		
* Percentages are calculated based on total net assets.		(A) Excludes short-term investments	used for cash management purposes.

Material Fund Changes

There were no material changes during the reporting period.

Changes in and Disagreements with Accountants

There were no changes in or disagreements with accountants during the reporting period.

Additional Information

For additional information about the Fund; including its prospectus, financial information, holdings, and proxy voting, visit or call:

• 1-877-655-1287

NEXPOINT

· https://www.nexpoint.com/nexpoint/funds/nexpoint-merger-arbitrage-fund/

Householding

Rule 30e-1 of the Investment Company Act of 1940 permits funds to transmit only one copy of a proxy statement, annual report or semi-annual report to shareholders (who need not be related) with the same residential, commercial or electronic address, provided that the shareholders have consented in writing and the reports are addressed either to each shareholder individually or to the shareholders as a group. This process is known as "householding" and is designed to reduce the duplicate copies of materials that shareholders receive and to lower printing and mailing costs for funds. Shareholders who have consented to receive a single annual or semi-annual shareholder report at a shared address may revoke this consent by contacting us at 1-877-655-1287.

NexPoint Funds I NexPoint Merger Arbitrage Fund / Class Z Shares - HMEZX Annual Shareholder Report - June 30, 2024 NEX-TSR-MAF